Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an announcement.
ResMed’s chief financial officer, Brett Sandercock, has reported the sale of 1,000 shares of ResMed common stock in a transaction dated March 2, 2026, at a price of $254.30 per share. Following this planned sale, conducted under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025, Sandercock continues to hold 84,495 shares directly, indicating he retains a significant equity stake in the company.
The disclosed transaction reflects ongoing executive share management rather than a broad change in corporate strategy or capital structure, and it signals continued alignment between the CFO’s financial interests and those of other shareholders. Investors may view the filing as routine insider trading activity governed by regulatory safeguards, offering transparency into executive ownership without suggesting a shift in ResMed’s operational outlook.
The most recent analyst rating on (AU:RMD) stock is a Hold with a A$39.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a medical technology company specializing in devices and software that diagnose, treat, and manage sleep apnea and other chronic respiratory conditions. The company focuses on sleep and respiratory care solutions for patients and healthcare providers globally, with its common stock traded under the ticker RMD.
Average Trading Volume: 1,113,865
Technical Sentiment Signal: Hold
Current Market Cap: A$53.37B
For a thorough assessment of RMD stock, go to TipRanks’ Stock Analysis page.